Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Updates on targeting PI3 kinase gamma in myeloid malignancies

Andrew Lane • 18 Sep 2026
Acute Myeloid Leukemia Chronic Myelomonocytic Leukemia Leukemia Myelodysplastic Syndromes Azacitidine Eganelisib Venetoclax
GAVeL

Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents updates on targeting PI3 kinase gamma in myeloid malignancies. Dr Lane discusses the potential of PI3 gamma inhibition as a single agent in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as in combination with chemotherapy, hypomethylating agents, or venetoclax. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrew Lane

Emerging targets, biomarker strategies and cancer stem cell approaches in AML
9:53
Emerging targets, biomarker strategies and cancer stem cell approaches in AML
Aditi Shastri et al. • 20 Sep 2026
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025
Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
0:47
Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
Andrew Lane • 6 Dec 2025
Approaching treatment decisions in newly diagnosed BPDCN
0:52
Approaching treatment decisions in newly diagnosed BPDCN
Andrew Lane • 6 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals